STOCK TITAN

Vera Therapeutics Inc - VERA STOCK NEWS

Welcome to our dedicated news page for Vera Therapeutics (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vera Therapeutics's position in the market.

Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) reported positive data from the Phase 2b ORIGIN trial at Kidney Week 2023, supporting the potential of atacicept as a treatment for IgA nephropathy (IgAN). The company also presented strong financial results and a robust balance sheet, with upcoming milestones including the presentation of Phase 2b open-label extension data in Q1 2024 and full enrollment of Phase 3 ORIGIN 3 trial in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
earnings
-
Rhea-AI Summary
Vera Therapeutics announces positive results from the Phase 2b ORIGIN study of atacicept in patients with immunoglobulin A nephropathy (IgAN). Hematuria resolved in 80% of patients receiving atacicept compared to 5% in the placebo group. High serum levels of Gd-IgA1 were significantly reduced in patients on atacicept. The company is on track with enrollment for the Phase 3 ORIGIN 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Vera Therapeutics, Inc. will be participating in two investor conferences, the Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on November 6, 2023, and the 6th Annual Evercore ISI HealthCONx Conference on November 30, 2023. The company's management team will present and participate in one-on-one meetings at these conferences. Webcasts of the presentations will be available on the respective conference websites, and replays will be accessible on the Vera Therapeutics website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.32%
Tags
conferences
Rhea-AI Summary
Vera Therapeutics announces selection of abstracts on atacicept for poster presentations at ASN Kidney Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
Rhea-AI Summary
Vera Therapeutics to present at four investor conferences next month
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
conferences
-
Rhea-AI Summary
Vera Therapeutics, Inc. reported positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN. They also initiated the Phase 3 ORIGIN 3 trial for the same indication. The company has a strong balance sheet expected to fund operations until early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
clinical trial
Vera Therapeutics Inc

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.39B
31.38M
5.76%
91.66%
11.54%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Brisbane

About VERA

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.